Meet the team of senior leaders driving Real Endpoints’s strategy and success
Norman Selby, Chairman
Norman C. Selby has been active in the healthcare world for over 30 years in a variety of operating, investment, consulting, and Board roles. His primary activity today is serving as Executive Chairman of two innovative healthcare information businesses focused on the changing US reimbursement landscape: Real Endpoints llc and Reimbursement Intelligence llc.
Mr. Selby is also on the Board of three healthcare product companies: Infinity Pharmaceuticals, a leading public (INFI) oncology biotech company, Metamark Genetics, a start-up oncology diagnostics company, and Merz Group GmbH, a global specialty pharma company based in Frankfurt, Germany. He has previously served on the Boards of Millennium Pharmaceuticals (MLNM) and several other private healthcare companies. During the past decade Mr. Selby led the growth and development of three healthcare companies, all of which had successful exits to larger strategic enterprises: Physicians Interactive Inc, which he built as Executive Chairman through 4 acquisitions from 2008 – 2012, and sold in 2013 to Merck GHIF; Windhover Information, which he invested in and became Executive Chairman of in 2004, and which was acquired by Reed Elsevier in 2008; and TransForm Pharmaceuticals, where he was CEO and President from 2001 – 2004, and which was acquired by Johnson & Johnson. Mr. Selby spent the bulk of his career (1978 – 1997) at McKinsey & Company where he was Director (Senior Partner) in the firm’s New York office. He held several leadership roles at McKinsey, including head of the firm’s Global Pharmaceuticals and Medical Products Practice. From 1987-1989, Mr. Selby took a leave of absence from McKinsey to serve as Chief Operating Officer of the New York Blood Center, the largest community blood organization in the country, where he led its financial and operational turnaround. After McKinsey he went to Citicorp/Citigroup where he was an Executive Vice President. Mr. Selby serves on the Board of Trustees of the Central Park Conservancy, the Memorial Sloan-Kettering Cancer Center and the Ralph Lauren Center for Cancer Care and Prevention, all based in New York City. He is also a member of the advisory board of the Harvard Business School’s Healthcare Initiative, and a Board member of the National Parks Conservation Association in Washington D.C. Mr. Selby holds a B.A. in Architecture from Yale College and an M.B.A. with Distinction from the Harvard Graduate School of Business Administration.
Roger Longman, Chief Executive Officer
Roger Longman is CEO of Real Endpoints, a start-up company focused on pharmaceutical reimbursement, and aiming to help both payers and product developers improve the value of pharmacotherapy. Its first product assesses – systematically, objectively, and transparently – the value of drugs relative to their competitors.
Until November 2009, Longman was Managing Director, Pharma at Elsevier Business Intelligence, a Reed Elsevier company. He has been involved with the health-care industry for more than 25 years.
From 1990 through 2008, Longman was co-CEO and managing director of Windhover, an information company providing sophisticated analysis and data around pharmaceutical and medical device business strategy through publications, databases and conferences. Longman co-founded and built the company through internal development (with publications such as IN VIVO, Start-Up and The RPM Report, several databases, including The Strategic Transactions Database; and a series of senior-executive conferences), and through acquisition.
In 2008, Windhover was acquired by Reed Elsevier and merged with its FDC Reports division (publishers of The Pink Sheet, The Gray Sheet and many other medical-industry newsletters), creating Elsevier Business Intelligence. Longman ran the combined group’s pharmaceutical business until he left in 2010 to begin working on Real Endpoints with Norman Selby, who had been Windhover’s chairman and lead investor.
Over the years, Mr. Longman has become recognized as an expert in biopharmaceutical strategy and often speaks at key industry events organized by important trade organizations, investment banks, venture capital firms and leading pharma and biotech companies. He lectures regularly at several leading universities and co-directed the Wharton-Windhover pharmaceutical program at The Wharton School. Mr. Longman completed his BA at Cornell University and an MA at the University of North Carolina at Chapel Hill, and then taught for three years at the European division of the University of Maryland.
Julie Eskay-Eagle, VP of Strategy & Corporate Development
Julie is responsible for Real Endpoints’ strategic vision and corporate development, including partnerships and data base licensing. Julie was Head of Health Care Investments for The Wellcome Trust, from 2000-2010. Prior to The Wellcome Trust, Julie was a Vice President in the Health Care Group at Lazard Freres and a member of Lazard Technology Partners. Before joining Lazard, Julie was a Health Care Specialist at McKinsey & Co. under Norman Selby.
John Whang, MD, COO, Reimbursement Intelligence
John joined RI from McKinsey, where he was a senior consultant in its Health Care Practice, focusing on payer, provider, device and pharmaceutical clients. Before McKinsey, John was Director of Non-Invasive Cardiovascular Services at Morristown Medical Center in Morristown, NJ, which is the second largest cardiac program in the Northeast. John managed all aspects of inpatient and outpatient cardiovascular services while actively practicing cardiology. He led the introduction of cutting-edge technologies such as intra-cardiac echo (ICE) to enable the growth of innovative catheter-based programs including PFO closure and transcatheter valve. John has an AB from Harvard and an MD from Columbia University’s College of Physicians and Surgeons.